Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma Clinical Trial

Official title:

Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00556049
• Other study ID #: 07-212
• Status: Completed
• Phase: Phase 2
• First received: November 7, 2007
• Last updated: March 24, 2015
• Start date: December 2007
• Est. completion date: December 2014

Study information

• Verified date: March 2015
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to determine if the combination of sunitinib and gemcitabine is effective in treating patients with metastatic renal cell carcinoma. The safety of this combination will also be studied. Sunitinib is approved by the FDA for the treatment of renal cell carcinoma. However, some patients' cancers do not respond to treatment or stops responding after initially responding. Gemcitabine is a chemotherapy drug that is approved by the FDA for the treatment of pancreatic cancer and several other cancers. It is not approved for the treatment of renal cell carcinoma. Previous research has suggested that combining gemcitabine with sunitinib may have some effectiveness in treating metastatic renal cell carcinoma.

Description:

• Participants will receive study treatment as an outpatient. Study treatment will be given in 3-week cycles.

• Sunitinib will be taken orally once per day for the first two weeks (days 1-14) of each treatment cycle.

• Gemcitabine will be given intravenously at the study clinic on days 1 and 8 of each treatment cycle.

• Before receiving sunitinib and gemcitabine on day 1 of each cycle the following will be performed: physical exam, performance status assessment and blood work. Before receiving gemcitabine on day 8 the following will be performed: physical exam, performance status assessment and blood work. Every 3 cycles a CT scan will be performed to measure the tumor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: December 2014
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically proven metastatic renal cell carcinoma with any sarcomatoid histology or poor-risk features as defined by having 3 or more of the following characteristics:

• PS > 1, high serum lactate dehydrogenase

• low hemoglobin

• high "corrected" serum calcium

• 2 or more sites of metastatic disease

• time from initial diagnosis to evidence of metastatic disease 12 months or less

• Evidence of unidimensional measurable disease based on RECIST criteria, with at least 1 measurable lesion

• Male or female, 18 years of age or older

• ECOG performance status of 0-2

• Patients with brain metastasis can only be included of they were treated 4 weeks or more prior to enrollment with whole brain radiation and the effects of treatment have resolved

• Resolution of all acute toxic effects of prior therapy, radiotherapy or surgical procedure to NCI CTCAE version 3.0 grade of 1 or less

• Laboratory values as outlined in the protocol

• 2 weeks or more must have elapsed from the time of major surgery or radiation therapy prior to the day of registration

• No anticipated need for major surgical procedure during the course of the study

Exclusion Criteria:

• Prior treatment with sunitinib or gemcitabine

• More than one prior systemic therapy of any kind for renal cell carcinoma

• Uncontrolled high blood pressure

• Any prior history of hypertensive crisis or hypertensive encephalopathy

• Any of the following within the 6 months prior to study drug administration:

myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack, or symptomatic congestive heart failure

• Ejection fraction < 30%

• Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication

• NCT CTCAE grade 3 or higher hemorrhage within 4 weeks of starting treatment

• Significant vascular disease

• Current grade 3 or higher cardiac dysrhythmia or QT prolongation

• Concurrent use of proarrhythmic medications including terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, and flecainide

• Pregnancy or breastfeeding or inadequate contraception

• Evidence of bleeding diathesis or coagulopathy

• Serious, non-healing wound, ulcer or bone fracture

• Psychiatric illness/social situation that would limit compliance with study requirements

• Previous diagnosis of concurrent malignancy requiring active systemic therapy

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Neoplasm Metastases
• Neoplasm Metastasis
• Renal Cell Carcinoma

Intervention

Drug:
• Gemcitabine
Intravenously on days 1 and 8 of each 21-day treatment cycle.
• Sunitinib
Orally on days 1-14 of each 21-day treatment cycle

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center`	Boston	Massachusetts
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (4)

Lead Sponsor	Collaborator
Massachusetts General Hospital	Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To Determine the Overall Response Rate of Combination Therapy With Gemcitabine and Sunitinib in Sarcomatoid and/or Poor-risk mRCC Patients as First Line Therapy.		Until disease progression	No